The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
about
High throughput screening to identify natural human monoamine oxidase B inhibitorsParkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's DiseaseIn vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Use of monoamine oxidase inhibitors in chronic neurodegeneration.Lack of tyramine pressor response effect with oral CX157: A specific reversible MAOI.Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity.Effects of eldepryl on glial cell proliferation and activation in the substantia nigra and striatum in a rat model of Parkinson's disease.High intake of dietary tyramine does not deteriorate glucose handling and does not cause adverse cardiovascular effects in mice.AIM interneurons mediate feeding suppression through the TYRA-2 receptor in C. elegans.
P2860
Q31083774-B882C036-9D27-49F4-8BC6-ECA35277A3FCQ36164724-1EC7ED4D-53BF-4522-AB92-770713289D75Q36512635-9904EFB0-44C2-4A6C-A8BD-4A2459E32372Q36969769-AF2A769B-6622-41F8-A15B-E2A49A485004Q38223072-3A6CCC70-9289-49CF-A615-6860F159AFA2Q38260834-18A45B1C-4035-4723-8D55-540DA7597064Q38545359-26159110-8C47-4CD5-8E70-7EB8E0504647Q39044780-24AD0E86-7A3D-4B1B-BCF2-2F7E300E24B1Q39284988-6E9D4A1F-D4C5-42A0-B281-546A1C8D2764Q39368224-5D745A91-9A54-418B-B4E9-7E578C38D0F8Q48271930-89AC2445-FDC0-4065-999E-DE09785C5C97Q51293187-B0118C78-73B6-416C-A3F0-8BDD503AA26BQ55076223-4808837F-2E31-41F6-976B-8A55B68A27F6
P2860
The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The monoamine oxidase type B i ...... ease: is tyramine a challenge?
@en
The monoamine oxidase type B i ...... ease: is tyramine a challenge?
@nl
type
label
The monoamine oxidase type B i ...... ease: is tyramine a challenge?
@en
The monoamine oxidase type B i ...... ease: is tyramine a challenge?
@nl
prefLabel
The monoamine oxidase type B i ...... ease: is tyramine a challenge?
@en
The monoamine oxidase type B i ...... ease: is tyramine a challenge?
@nl
P2860
P921
P356
P1476
The monoamine oxidase type B i ...... ease: is tyramine a challenge?
@en
P2093
Jack J Chen
Jayne R Wilkinson
P2860
P304
P356
10.1177/0091270011406279
P577
2011-05-31T00:00:00Z